Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,147
Employees1,147
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,147
Employees1,147

EXEL Key Statistics

Market cap
12.38B
Market cap12.38B
Price-Earnings ratio
18.39
Price-Earnings ratio18.39
Dividend yield
Dividend yield
Average volume
2.14M
Average volume2.14M
High today
$46.30
High today$46.30
Low today
$43.68
Low today$43.68
Open price
$44.20
Open price$44.20
Volume
2.50M
Volume2.50M
52 Week high
$49.62
52 Week high$49.62
52 Week low
$31.90
52 Week low$31.90

Stock Snapshot

The current Exelixis(EXEL) stock price is $46.19, with a market capitalization of 12.38B. The stock trades at a price-to-earnings (P/E) ratio of 18.39.

During the trading session on 2026-01-08, Exelixis(EXEL) shares reached a daily high of $46.30 and a low of $43.68. At a current price of $46.19, the stock is +5.8% higher than the low and still -0.2% under the high.

Trading activity shows a volume of 2.5M, compared to an average daily volume of 2.14M.

Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $31.90.

Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $49.62 and a low of $31.90.

EXEL News

TipRanks 21h
Exelixis, Natera announce collaboration on STELLAR-316 trial

Exelixis (EXEL) and Natera (NTRA) announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 pivotal trial will...

Simply Wall St 23h
How Investors May Respond To Exelixis Pipeline Updates Amid Cabometyx Exclusivity and Competition Concerns

Exelixis recently announced that President and CEO Michael M. Morrissey, Ph.D., had provided a corporate overview at the J.P. Morgan 2026 Healthcare Conference,...

How Investors May Respond To Exelixis Pipeline Updates Amid Cabometyx Exclusivity and Competition Concerns
TipRanks 3d
Exelixis downgraded to Underperform from Neutral at BofA

BofA downgraded Exelixis (EXEL) to Underperform from Neutral with a price target of $41, down from $43, citing valuation and limited high-impact catalysts seen...

Analyst ratings

50%

of 22 ratings
Buy
45.5%
Hold
50%
Sell
4.5%

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.